14 March 2020 : Case report
Durable Response to Brentuximab Vedotin-Based Chemotherapy in Refractory Hodgkin Lymphoma with Central Nervous System (CNS) Involvement
Unusual or unexpected effect of treatment, Rare disease
DOI: 10.12659/AJCR.921657
Am J Case Rep 2020; 21:e921657
HTML version available soon